Difference between revisions of "Zaidi AH, et al. Ann. Surg. (2017) cited as Ref 365 in DOI: 10.1038/s41392-020-0110-5 (Q9628)"
Jump to navigation
Jump to search
(Created claim: Volume (P103): 266, #quickstatements; #temporary_batch_1590009084631) |
(Created claim: title (P93): PI3K/mTOR dual inhibitor LY3023414 demonstrates potent antitumor efficacy against esophageal adenocarcinoma in a rat model, #quickstatements; #temporary_batch_1590010982689) |
||
| Property / title | |||
| + | PI3K/mTOR dual inhibitor LY3023414 demonstrates potent antitumor efficacy against esophageal adenocarcinoma in a rat model (English) | ||
| Property / title: PI3K/mTOR dual inhibitor LY3023414 demonstrates potent antitumor efficacy against esophageal adenocarcinoma in a rat model (English) / rank | |||
| + | Normal rank | ||
Revision as of 22:00, 20 May 2020
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
| Language | Label | Description | Also known as |
|---|---|---|---|
| English |
Zaidi AH, et al. Ann. Surg. (2017) cited as Ref 365 in DOI: 10.1038/s41392-020-0110-5
|
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
|
Statements
Zaidi AH
0 references
2017
0 references
Ann. Surg.
0 references
266
0 references
PI3K/mTOR dual inhibitor LY3023414 demonstrates potent antitumor efficacy against esophageal adenocarcinoma in a rat model (English)
0 references
